Skip to main content

CORRECTION article

Front. Immunol. , 10 October 2017

Sec. Primary Immunodeficiencies

Volume 8 - 2017 | https://doi.org/10.3389/fimmu.2017.01244

Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content

This article is a correction to:

  1. Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content

    1. Read original article
\r\nKerry Dobbs&#x;Kerry Dobbs1†Giovanna Tabellini&#x;Giovanna Tabellini2†Enrica CalzoniEnrica Calzoni3Ornella PatriziOrnella Patrizi2Paula MartinezPaula Martinez4Silvia Clara GilianiSilvia Clara Giliani3Daniele MorattoDaniele Moratto3Waleed Al-HerzWaleed Al-Herz5Caterina Cancrini,Caterina Cancrini6,7Morton CowanMorton Cowan8Jacob BleesingJacob Bleesing9Claire BoothClaire Booth10David BuchbinderDavid Buchbinder11Siobhan O. Burns,Siobhan O. Burns10,12Talal A. ChatilaTalal A. Chatila13Janet ChouJanet Chou13Vanessa Daza-CajigalVanessa Daza-Cajigal10Lisa M. Ott de BruinLisa M. Ott de Bruin13Maite Teresa de la MorenaMaite Teresa de la Morena14Gigliola Di Matteo,Gigliola Di Matteo6,7Andrea Finocchi,Andrea Finocchi6,7Raif GehaRaif Geha13Rakesh K. GoyalRakesh K. Goyal15Anthony HaywardAnthony Hayward16Steven HollandSteven Holland17Chiung-Hui HuangChiung-Hui Huang18Maria G. KanariouMaria G. Kanariou19Alejandra KingAlejandra King20Blanka KaplanBlanka Kaplan21Anastasiya KlevaAnastasiya Kleva21Taco W. KuijpersTaco W. Kuijpers22Bee Wah LeeBee Wah Lee18Vassilios LougarisVassilios Lougaris23Michel MassaadMichel Massaad13Isabelle MeytsIsabelle Meyts24Megan MorsheimerMegan Morsheimer25Benedicte NevenBenedicte Neven26Sung-Yun PaiSung-Yun Pai27Nima Parvaneh,Nima Parvaneh28,29Alessandro PlebaniAlessandro Plebani23Susan ProckopSusan Prockop30Ismail ReisliIsmail Reisli31Jian Yi SohJian Yi Soh18Raz SomechRaz Somech32Troy R. TorgersonTroy R. Torgerson33Yae-Jean KimYae-Jean Kim34Jolan E. WalterJolan E. Walter35Andrew R. Gennery,Andrew R. Gennery36,37Sevgi KelesSevgi Keles31John P. ManisJohn P. Manis38Emanuela MarcenaroEmanuela Marcenaro39Alessandro MorettaAlessandro Moretta39Silvia Parolini*&#x;Silvia Parolini2*‡Luigi D. Notarangelo*&#x;\r\nLuigi D. Notarangelo1*‡
  • 1Laboratory of Host Defenses, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
  • 2Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
  • 3“A. Nocivelli Institute for Molecular Medicine”, Pediatric Clinic, University of Brescia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Italy
  • 4Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina
  • 5Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait
  • 6DPUO, Division of Immuno-Infectivology, University Department of Pediatrics, Bambino Gesù Children’s Hospital, Rome, Italy
  • 7School of Medicine, University of Tor Vergata, Rome, Italy
  • 8Pediatric Allergy Immunology and Blood and Marrow Transplant Division, University of California, San Francisco, Benioff Children’s Hospital, San Francisco, CA, United States
  • 9Division of Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
  • 10Institute for Immunity and Transplantation, University College London, London, United Kingdom
  • 11Division of Pediatric Hematology, Children’s Hospital Orange County, University of California Irvine, Orange County, CA, United States
  • 12Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom
  • 13Division of Immunology, Boston Children’s Hospital, Boston, MA, United States
  • 14Division of Allergy and Immunology, Southwestern Medical Center, University of Texas, Dallas, TX, United States
  • 15Division of Hematology/Oncology/BMT, Children’s Mercy Hospital & Clinics, Kansas City, MO, United States
  • 16Department of Pediatrics, Brown University, Providence, RI, United States
  • 17Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
  • 18Department of Paediatrics, National University Hospital, Singapore, Singapore
  • 19Department of Immunology-Histocompatibility, “Aghia Sophia” Children’s Hospital, Athens, Greece
  • 20Division of Pediatric Immunology, Hospital Luis Calvo Mackenna, Santiago, Chile
  • 21Department of Pediatrics, Division of Allergy and Immunology, Hofstra Northwell School of Medicine, Hofstra University, Great Neck, NY, United States
  • 22Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children’s Hospital, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands
  • 23Department of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy
  • 24Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium
  • 25Transplantation Branch, Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States
  • 26Pediatric Hematology-Immunology Department, Hospital Necker-Enfants Malades, Institute Imagine, AP-HP, Paris Descartes University, Sorbonne-Paris-Cité, Paris, France
  • 27Division of Hematology-Oncology, Boston Children’s Hospital, Boston, MA, United States
  • 28Division of Allergy and Clinical Immunology, Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran
  • 29Research Center for Immunodeficiencies, Children’s Medical Center, Tehran, Iran
  • 30Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States
  • 31Division of Pediatric Immunology and Allergy, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
  • 32Pediatric Immunology Unit, The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • 33Department of Pediatrics and Immunology, Seattle Children’s Hospital, University of Washington, Seattle, WA, United States
  • 34Division of Infectious Diseases and Immunodeficiency, Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea
  • 35Division of Pediatric Allergy/Immunology, University of South Florida at Johns Hopkins All Children’s Hospital, St. Petersburg, FL, United States
  • 36Department of Paediatric Immunology, Great North Children’s Hospital, Newcastle Upon Tyne, United Kingdom
  • 37Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom
  • 38Department of Laboratory Medicine, Boston Children’s Hospital, Boston, MA, United States
  • 39Molecular Immunology Laboratories, Department of Experimental Medicine, University of Genoa, Genoa, Italy

A corrigendum on

Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content
by Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, et al. Front Immunol (2017) 8:798. doi: 10.3389/fimmu.2017.00798

There was a mistake in the authorship. The name of Nima Parvaneh was unintentionally omitted. Dr. Parvaneh has contributed biological specimens and clinical and immunological data from patient P66 included in the manuscript, and as such he should be included in the authorship. The authors apologize for the mistake. This error does not change the scientific conclusions of the article in any way.

With the inclusion of Dr. Parvaneh’s name in the authorship, the paragraph of Author Contributions should also be corrected as follows:

JM, EM, AM, SP, and LN designed the study, interpreted the data, and wrote the manuscript; KD, GT, EC, OP, PM, SG, and DM performed experiments, acquired and analyzed the data; WA-H, CC, MC, JB, CB, DB, SB, TC, JC, VD-C, LOdB, MTdlM, GM, AF, RG, RKG, AH, SH, C-HH, MK, AlKi, BK, AnKl, TK, BL, VL, MiMa, IM, MeMo, BN, S-YP, NP, AP, SP, IR, JS, RS, TT, Y-JK, JW, AG, and SK contributed patient samples and clinical and immunological data; all authors have revised the work for its intellectual content, have approved its final version and have agreed to be accountable for all aspects related to the accuracy and integrity of the work.

This correction does not change the scientific conclusions of the article in any way.

Author apologizes for these errors and thank you for your consideration.

The original has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: natural killer cells, recombinase-activating genes, non-homologous end joining, immunodeficiency, CD56, interferon-γ, degranulation

Citation: Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J, Booth C, Buchbinder D, Burns SO, Chatila TA, Chou J, Daza-Cajigal V, Ott de Bruin LM, de la Morena MT, Di Matteo G, Finocchi A, Geha R, Goyal RK, Hayward A, Holland S, Huang C-H, Kanariou MG, King A, Kaplan B, Kleva A, Kuijpers TW, Lee BW, Lougaris V, Massaad M, Meyts I, Morsheimer M, Neven B, Pai S-Y, Parvaneh N, Plebani A, Prockop S, Reisli I, Soh JY, Somech R, Torgerson TR, Kim Y-J, Walter JE, Gennery AR, Keles S, Manis JP, Marcenaro E, Moretta A, Parolini S and Notarangelo LD (2017) Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Front. Immunol. 8:1244. doi: 10.3389/fimmu.2017.01244

Received: 10 September 2017; Accepted: 19 September 2017;
Published: 10 October 2017

Edited and Reviewed by: Megan Anne Cooper, Washington University in St. Louis, United States

Copyright: © 2017 Dobbs, Tabellini, Calzoni, Patrizi, Martinez, Giliani, Moratto, Al-Herz, Cancrini, Cowan, Bleesing, Booth, Buchbinder, Burns, Chatila, Chou, Daza-Cajigal, Ott de Bruin, de la Morena, Di Matteo, Finocchi, Geha, Goyal, Hayward, Holland, Huang, Kanariou, King, Kaplan, Kleva, Kuijpers, Lee, Lougaris, Massaad, Meyts, Morsheimer, Neven, Pai, Parvaneh, Plebani, Prockop, Reisli, Soh, Somech, Torgerson, Kim, Walter, Gennery, Keles, Manis, Marcenaro, Moretta, Parolini and Notarangelo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Silvia Parolini, c2lsdmlhLnBhcm9saW5pQHVuaWJzLml0;
Luigi D. Notarangelo, bHVpZ2kubm90YXJhbmdlbG8yQG5paC5nb3Y=

†These authors have contributed equally to this work.

‡These authors have contributed equally to this work.

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

Man ultramarathon runner in the mountains he trains at sunset

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more